Curapod, a Telangana-based healthtech innovation by Litemed India, has launched India’s first personalized wearable for non-invasive, drug-free pain relief, bringing a clinically validated solution to a market long dominated by medications, topical treatments, and clinic-based therapies. The wearable’s dual registration with the CDSCO and the U.S. FDA underscores its regulatory credibility and readiness for broad clinical and consumer adoption.

Built to support over 30 musculoskeletal pain conditions, Curapod is seeing early adoption across physiotherapy networks and wellness clinics, as well as among consumers managing chronic and activity-related pain at home. The device leverages medical-grade photobiomodulation, delivering red and near-infrared light to stimulate cellular repair, reduce inflammation, and accelerate recovery—often with users reporting relief within 30 minutes of use.

A core differentiator is Curapod’s adaptive engine, which dynamically adjusts therapy intensity in real time based on muscle response and user comfort. This personalization enables consistent, targeted relief while generating data that clinicians can review remotely to track progress, refine therapy programs, and deliver measurable outcomes blending clinical precision with everyday usability.

Personalization extends through a companion mobile app that customizes therapy plans, tracks usage and pain trends, and supports remote monitoring. This approach shifts pain management from passive, episodic care to continuous, outcome-driven therapy, without the risks associated with prolonged medication use.

Manufactured entirely in India, Curapod is designed for accessibility and scale, with partnerships across wellness chains and physiotherapy providers to ensure reach—including tier-2 and tier-3 cities. By aligning regulatory rigor, adaptive technology, and local manufacturing, Curapod positions itself at the intersection of digital health, wearables, and non-invasive therapy bringing personalized pain relief into everyday life.